Q1 2024 EPS Estimates for Cocrystal Pharma, Inc. (NASDAQ:COCP) Boosted by HC Wainwright

Cocrystal Pharma, Inc. (NASDAQ:COCP) – Analysts at HC Wainwright upped their Q1 2024 earnings per share (EPS) estimates for Cocrystal Pharma in a research note issued to investors on Thursday, April 4th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.56) per share for the quarter, up from their previous forecast of ($0.57). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($2.18) per share. HC Wainwright also issued estimates for Cocrystal Pharma’s Q2 2024 earnings at ($0.57) EPS, Q4 2024 earnings at ($0.59) EPS, FY2024 earnings at ($2.31) EPS and FY2025 earnings at ($1.47) EPS.

Cocrystal Pharma Trading Up 8.5 %

Shares of Cocrystal Pharma stock opened at $1.60 on Monday. The stock has a fifty day simple moving average of $1.50 and a 200 day simple moving average of $1.67. Cocrystal Pharma has a 12-month low of $1.33 and a 12-month high of $3.29. The company has a market capitalization of $16.22 million, a P/E ratio of -0.80 and a beta of 1.34.

Cocrystal Pharma (NASDAQ:COCP) last announced its quarterly earnings results on Thursday, March 28th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.13.

Institutional Investors Weigh In On Cocrystal Pharma

A hedge fund recently raised its stake in Cocrystal Pharma stock. Renaissance Technologies LLC raised its holdings in Cocrystal Pharma, Inc. (NASDAQ:COCP) by 5.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 119,828 shares of the company’s stock after purchasing an additional 5,800 shares during the quarter. Renaissance Technologies LLC owned 1.18% of Cocrystal Pharma worth $238,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 6.72% of the company’s stock.

About Cocrystal Pharma

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections.